diabetestalk.net

Insulin Pumps With Cgm

Insulin Pump And Cgm Usage In The United States And Germany

Insulin Pump And Cgm Usage In The United States And Germany

Go to: Methods In the US, the survey responses were received from subjects attending 15 diabetes clinics (an average of 10 subjects per practice), from pump users at the yearly Taking Control of Your Diabetes conference (106), and from an online survey (281). In GER, staff at diabetes specialty practices handed out surveys. Nineteen practices sent questionnaires back with an average of 26 subjects per practice. Demographic information was collected (gender, age group, year of diagnosis, years of pump wear, number of different insulin pumps worn, and last HbA1c), followed by 20 pump-usage questions. The pump questions addressed items like pump model, choice of IIS, and frequency of unexplained high blood sugars, occlusion alarms, need to change IIS early due to a high blood sugar, and so on. In GER, 1 additional question about CGM familiarity was asked, while 11 additional questions regarding CGM usage were asked in the US. The questionnaires did not contain information that allowed identification of subjects. Selection of subjects was inclusive without brand preference. The survey was conducted in both countries between the end of November 2013 and middle of February 2014. Copies of either version of the survey can be provided on demand. To compile results, responses were entered manually from the questionnaires into an Excel spread sheet. Care was taken to identify and correct data entry errors by running appropriate checks. Seven duplicate responses, 4 responses that lacked credibility, and 5 that were <50% complete were identified and deleted by 1 of the authors who is a diabetes clinical specialist and wears an insulin pump (JW). Not every question was answered by each participant, so the number of total responses for a given question was often below the total numbe Continue reading >>

Usa Insulin Pump Market & Users, Cgm (continuous Glucose Monitoring) Market & Users, Reimbursement Policy (by States), Diabetes (type1 & 2) Population, Deal Types, Clinical Trials & Forecast

Usa Insulin Pump Market & Users, Cgm (continuous Glucose Monitoring) Market & Users, Reimbursement Policy (by States), Diabetes (type1 & 2) Population, Deal Types, Clinical Trials & Forecast

United States CGM (Continuous Glucose Monitor) Market to be more than US$ 2 Billion in Future CGM (Continuous Glucose Monitor) is extremely important across all age groups to manage diabetes efficiently. In the United State, the market of CGM has a huge potential in coming years. From the year 2009 to 2016, Continuous Glucose Monitor users have grown to 35 percent. Many private insurers have started reimbursing CGM based on certain criteria in the United States. Many experts think that CGM is the best tool for diabetes management. For those having several diabetes complications, Continuous Glucose Monitor is very much compatible with that. In USA by States, Reimbursements of Insulin Pumps, CGM, Diabetes Supplies According to Renub Research report, we have enclosed many State sponsored programmes, which covers insulin pumps under equipment and supplies. The report also provides reimbursement details on the CGM either by the federal health plan or by the State-sponsored health plan. Nearly every state facilitates diabetes supplies to their city but not all state provides insulin pump. For the state-regulated health insurance policies, all the state law diabetes mandates and least coverage required. Leading companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training Model covered in the Report In this report we have covered, healthcare providers, diabetes educator and certified product trainer etc give inclusive training to new patients. Moreover, via online portal companies also facilitates training to the new pump user to review the training materials. A complete flow chart of training model of all the 4 companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care is covered in this report. Renub Research latest stu Continue reading >>

Us Med Launches Insulin Pump And Cgm Platform Through Their “rapid Response Care Program”

Us Med Launches Insulin Pump And Cgm Platform Through Their “rapid Response Care Program”

is pleased to announce that they have added Insulin Pump and Continuous Glucose Monitoring (CGM) supplies to assist in the treatment of Diabetic patients. Over the past twenty years, US MED has provided medical supplies to over 600,000 Diabetic patients. The Mission at US MED is to provide value-added services that enhance patient quality of life and reduce the overall costs of care. From removing the patient’s burden of insurance claims processing, to helping patients obtain prescriptions directly from their physician, US MED is a patient advocate that assists in navigating through the complex world of diabetes care. The addition of Insulin Pumps & CGM enables US MED to provide next level enhancements in proactively managing the diabetic disease state. With the recent Medicare announcement for reimbursement on CGM product codes, US Med is well positioned to begin offering treatment for this patient base. US MED is one of the sole providers for DME under Competitive Bid, as well as an active member for Medicaid and regional & national private health plans. US Med’s recent launch of the “Rapid Response Care Program” for Insulin Pump & CGM, is a patient-centric approach to enhance therapy treatments, with a focus on positive patient outcomes and high patient satisfaction. Please visit US MED at www.usmed.com to learn more about their products and services. Continue reading >>

Minimed® 530g System

Minimed® 530g System

Diabetes shouldn't prevent you from living the life you want. Playing in the majors. Taking the stage. Falling in love. MiniMed 530G system with SmartGuard™ technology helps you better control your glucose levels and even takes action for you when you need it – so you can be free to experience life's exceptional moments. Worn on your body, the pump delivers tiny drops of rapid-acting insulin to match your needs. Change your pump tubing only once every two to three days. Bolus Wizard® calculator makes it easier to calculate mealtime insulin and may avoid insulin stacking.1 Set temporary basal rates and patterns around your activities. Get readings every five minutes, right on your pump. Track your glucose levels throughout the day, including the effects of food or exercise. Get alerted when you’re trending high or low, so you can make adjustments – ahead of time. MiniMed 530G system is an insulin pump that’s fully integrated with a glucose sensor to give you advanced diabetes control. It’s the only diabetes management system with SmartGuard™ technology that takes action for you and is proven to reduce your risk of lows*. And by helping you keep your glucose levels stable long-term, MiniMed system can help lower both your A1C and your risk of nerve, eye and kidney problems.2,3,4 A good night’s sleep can mean starting your day refreshed, ready to live the life you want. But when you’re living with diabetes, a restful sleep can sometimes feel out of reach. In fact, up to 75 percent of severe hypoglycemia happens at night.5 SmartGuard technology users experience about half as many nighttime lows* than those using a pump and sensor alone 6. Our exclusive SmartGuard technology mimics some of the functions of a healthy pancreas to provide you with advanced pr Continue reading >>

See Your Diabetes Data Together

See Your Diabetes Data Together

Get Insulin Insights on the Go! Running around town and wondering what happened to your glucose levels the last time you had a burrito? Glooko allows people with diabetes and their care team to sync, review and analyze their glucose levels in context with their medication, fitness, biometric and carb intake data – on the go. With the addition of Glooko’s support for popular insulin pumps and CGMs, patients and their care teams can easily get insulin insights, along with reminders, alerts and an understanding of how patients manage their diabetes. Views of glucose trends and the events that drive those trends are right in your pocket. Mobile views include summaries of glucose trends over time – by week, day of week and time of day. Users can graphically track how carb intake and insulin therapy impact glucose readings and identify what “events” – meals, exercise and medications – have an impact as well. Learn to understand and optimize basal and bolus rates in the moment, when trying to make decisions on what to eat, when to exercise and more. Why are readings low on Wednesday afternoon? Does the Friday happy hour really have such a big impact over the weekend? The Glooko Modal Day View enables patients and providers to see glucose trends for a particular day so evidence-based care adjustments can be made that improve health outcomes. The day of the week controller allows users to zoom in on data and uncover insightful trends. Summary statistics elucidate which days and what times are patients experiencing trouble spots. A lot can happen in a month. The Glooko Calendar View shows you trends at a high level for each month. Is the weekend warrior workout having the same effect each week? Did vacation dramatically impact your blood glucose levels for the perio Continue reading >>

5. All-in-one Cgm And Insulin Pump From Dexcom And Tandem Diabetes

5. All-in-one Cgm And Insulin Pump From Dexcom And Tandem Diabetes

Earlier this year, DexCom and Tandem Diabetes teamed up to develop a device that hopes to snag a big market share in the diabetes game: a combination continuous glucose monitor and insulin pump. Using Tandem's T:Slim touch-screen insulin pump as a platform, DexCom will bring its CGM knowhow to develop an all-in-one monitor-and-pump combo. And the benefits could be huge. There's just one combination device already on the market (Medtronic's ($MDT) Paradigm), but T:Slim is the world's smallest insulin pump and the only one with touch-screen controls. If DexCom and Tandem can keep the tech small and navigate the 510(k) process, their combination platform could be a hit in the diabetes world. Continue reading >>

Animas® Vibe® Insulin Pump & Continuous Glucose Monitoring System

Animas® Vibe® Insulin Pump & Continuous Glucose Monitoring System

*Patients must confirm CGM reading with a fingerstick test before taking action. **CGM readings may not be transmitted from the CGM to the pump while in the water. Important safety information The Animas® Vibe® Insulin Pump and CGM System is intended for the delivery of insulin and for continuous glucose monitoring (CGM) for the management of insulin-requiring diabetes. The Animas® Vibe® System’s CGM, which includes the Dexcom G4® PLATINUM Sensor and Transmitter, is indicated for detecting trends and tracking patterns in persons age 2 and older. The system is intended for single patient use and requires a prescription. Contraindications: Insulin pump therapy is not recommended for people unwilling or unable to test their blood glucose four to six times per day, unwilling or unable to see their healthcare professional regularly, or whose vision or hearing does not allow recognition of pump alerts, warnings, and alarms. The Animas® Vibe® Insulin Pump must be removed before MRI or CT scan, and the Dexcom G4® PLATINUM Sensor and Transmitter must be removed before MRI, CT scan, or diathermy treatment. Taking acetaminophen-containing medications while wearing the sensor may falsely raise sensor glucose readings. Warnings: Connecting to the pump before receiving the necessary training could result in serious injury or death. Younger children may inadvertently press the pump buttons and deliver insulin, which can lead to hypoglycemic events. Caregivers are responsible for helping to ensure safe and effective delivery of insulin to people in their care, including using the safety features on the Animas Vibe System to help prevent injury. CGM glucose readings are not to be used to make treatment decisions. The sensor and transmitter do not replace a blood glucose meter. Continue reading >>

The Future For Insulin Pump Companies: Who Will Survive?

The Future For Insulin Pump Companies: Who Will Survive?

www.diabeticinvestor.com As problems for Tandem continue, and with Johnson & Johnson abandoning the insulin pump market, it’s beginning to dawn on some people that we soon could live in a world with just two insulin pump companies – Medtronic and Insulet. [Editor’s Note: Johnson & Johnson reached out to us with the following information: “Animas continues to manufacture, deliver and support its products and provide the service our patients expect. We remain committed to our patients, and we intend to honor our warranty and do not anticipate any interruptions to patients’ pump therapy. If patients or potential patients have any concerns, they can contact Animas online or at 1-877-YES-PUMP.”] Ok, to be fair, Roche also has a pump, but their market presence is lacking. Also, to be fair, Bigfoot is working on a system, but it isn’t here yet. Plus, there is growing belief that patients can achieve optimum control using a CGM smart insulin pen system. Given where things stand today, the real possibility exists that when it comes to insulin pumps, patient choice will be very limited. This was a fear expressed by many when Medtronic signed an exclusive deal with UnitedHealthcare. Yet this agreement is not the cause of limited patient choice. Poor strategy is the real reason, as both Tandem and J&J have made mistakes that have put them in their current positions. Now, I will not list these mistakes as it serves no useful purpose; there is no need to go backward. What I will do, however, is offer a path forward for any company that is bold enough to take on Medtronic. Keep in mind that Diabetic Investor has been covering Medtronic since it was known as MiniMed and no one, and I mean no one, has come close to giving them a run for their money – EVER. The insulin pu Continue reading >>

The T:slim X2 Pump Is Up To 38% Smaller Than Other Pumps,1 But Is Packed With Big Features.

The T:slim X2 Pump Is Up To 38% Smaller Than Other Pumps,1 But Is Packed With Big Features.

*A prescription and additional training may be required to access certain future software updates. Offer only available to customers in the United States. 38% smaller than MiniMed 630G and 670G and at least 28% smaller than MiniMed 530G, Animas Vibe and Omnipod System. Data on file, Tandem Diabetes Care. Additional feature updates are not currently available for the t:slim X2 Pump with Dexcom G5 CGM integration and are subject to future FDA approvals. Charges may apply. Dexcom G5 Mobile CGM sold separately. CGM coverage may vary based on insurance. Please consult your CGM supplier for coverage information. Tested to a depth of 3 feet for 30 minutes (IPX7). CGM-based treatment requires fingersticks for calibration; may result in hypoglycemia if calibration not performed, when taking acetaminophen, or if symptoms/expectations do not match CGM readings. The Dexcom G5 Mobile CGM transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 Pump) and one consumer device (phone or tablet) at the same time. dQ&A USA Diabetes Connections Surveys, 2009-2017. Dexcom G5 Mobile CGM User Guide, 2017. Following your shared data requires the Dexcom Follow app. dQ&A USA Diabetes Connections Surveys, 2013-2017. Indications for Use: RX ONLY. The t:slim X2 Insulin Delivery System is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin for individuals 6 years of age or greater. The t:slim X2 Insulin Pump can be used solely for continuous insulin delivery and/or as part of the t:slim X2 System to receive and display continuous glucose measurements from the Dexcom G5 Mobile Sensor and Transmitter. The t:slim X2 System also includes continuous glucose monitoring (CGM) Continue reading >>

Continuous Glucose Monitoring.

Continuous Glucose Monitoring.

Get glucose values continuously. The Animas® Vibe® Insulin Pump is CGM-enabled, which means you have the option to receive glucose readings every 5 minutes on your Animas® Vibe® Insulin Pump, where the data can be viewed and analysed on the pump’s colour display*. Giving you the full picture. The major benefit of having a CGM-enabled insulin pump is that this functionality reveals a complete view of the glucose highs, lows and rates of change over time. This information complements fingerstick testing results and can be used to help guide therapy adjustments.† How it works. CGM components include a Sensor and a Transmitter. The Sensor is a disposable unit that is placed under the skin (the subcutaneous space) of your abdomen or upper buttocks. The Dexcom G4® PLATINUM Sensor continuously measures the glucose levels in your tissues (the interstitial fluid), not in the blood. The Transmitter is a reusable device that snaps into the Sensor Pod. The Transmitter wirelessly sends the sensor-measured glucose readings every 5 minutes to your Animas® Vibe® Insulin Pump, where the data can be viewed and analysed on the pump’s colour display.* CGM doesn’t replace fingerstick testing; rather, it works with it.† With trending graphs and directional arrows, the idea is to use CGM to determine the direction your glucose is headed and how fast, and then use your fingerstick test to figure out your insulin dose. About the sensor. The Dexcom G4® PLATINUM Sensor is a thin wire inserted underneath your skin with the help of an introducer needle. The Sensor is held in place with adhesive, similar to the way your infusion set is attached. CGM readings, measured by the Sensor, are sent from the Transmitter to the Animas® Vibe® Insulin Pump every 5 minutes.* To track how you Continue reading >>

Continuous Glucose Monitoring?

Continuous Glucose Monitoring?

what is continuous glucose monitoring Continuous Glucose Monitoring (CGM) technology enables you to monitor your glucose levels 24 hours a day through a sensor that sends the readings to a MiniMed® insulin pump (or your iphone – learn more). If used with the MiniMed® 640G you get the intelligence of SmartGuardTM to predict when you are approaching a low glucose level 30 minutes in advance and automatically stop insulin delivery. SmartGuardTM will automatically resume insulin delivery when your glucose levels recover1. In essence, CGM provides a more complete picture of your blood glucose levels by giving you early warnings of lows and highs that HbA1C and fingerstick testing alone cannot always identify. In fact, use of CGM has been shown to lower HbA1c levels2 and reduce the time of hypos3. HOW DOES CONTINUOUS GLUCOSE MONITORING WORK? The pump, when combined with the GuardianTM 2 Link transmitter and the enhanced EnliteTM glucose sensor, wirelessly transmits readings to your MiniMed® 640G. The readings are updated every five minutes and appear on the screen in colour. These regular updates can give you a clear understanding of how your glucose levels are tracking. The glucose sensor only needs to be changed every six days. Continue reading >>

Insulin Pump And Cgm Adherence

Insulin Pump And Cgm Adherence

Joe*, a 52-year-old security guard, had type 2 diabetes. His daily injections were not keeping his A1C below 8 consistently, so his clinician recommended an insulin pump to maintain a more stable blood glucose level. Joe was nervous about using a new device. When it arrived in the mail, he was overwhelmed by the instructions and wasn’t sure he could learn to use the pump on his own. He worried that the pump wouldn’t fit under his uniform and was embarrassed that his coworkers might see it. Joe was also concerned about the ongoing cost of treatment. Joe’s clinician thought he would benefit from additional support, so he helped Joe enroll in the Patient Support Program. Joe’s clinician wanted him to get a good start on treatment so he would be more likely to use the pump consistently. As part of the Patient Support Program, Joe’s clinician invited him to participate in an in-office group training session for patients starting on the insulin pump. Along with other patients, Joe learned more about the benefits of using an insulin pump and gained confidence in his ability to fill, apply, and replace his device. Joe’s Treatment Experience Nurse called to welcome him to the program and completed a barrier assessment, which was entered in the SmartCARE Platform and reported to Joe’s clinician through the Clinician Feedback Loop. Lack of education/training Lifestyle changes Medication routine and logistics Financial concerns The Treatment Experience Nurse listened to Joe’s concerns and answered his questions. She reassured him that the pump would be discreet and that it would not interfere with his job. She also suggested resources for reimbursement/benefits support and signed him up with co-pay assistance to help with his out of pocket cost. “Living With an In Continue reading >>

Animas® Vibe® Insulin Pump

Animas® Vibe® Insulin Pump

Features It’s Dexcom CGM enabled. The Animas Vibe can now double as a continuous glucose monitor using Dexcom G4 PLATINUM sensor technology. The Dexcom G4 PLATINUM sensors are indicated for up to 7 days consecutive wear. The Transmitter for the Dexcom system is water resistant up to 2.4m for 24 hours.* The reading is updated on the pump every 5 minutes and you can see if your glucose is stable, rising or falling at a glance. More on the advantages of CGM and the Dexcom G4 Platinum. Subsidised access to Dexcom G5 Mobile and Dexcom G4 PLATINUM CGM sensors and transmitters is available through the NDSS to children and young people aged under 21 years, living with type 1 diabetes, who meet specific criteria. Visit www.ndss.com.au/CGM for more information today. We think a pump that’s waterproof just makes sense. Our pumps are tested and proven waterproof at 3.6 metres for up to 24 hours.† So you get uninterrupted insulin delivery while swimming or taking a bath, and peace of mind when you have unexpected contact with water. Fine-Tuned Insulin Delivery. The Animas Vibe Insulin Pump Swiss-made motor offers basal rate increments as low as 0.025 U/hr (available range of 0.025 to 25 U/hr) and bolus increments as low as 0.05 U across the available range (0.05 to 35 U) to deliver precise increments of insulin to help the body’s changing needs. Fully Customisable Food Database. With the download cable included free with your pump, you can use the web based Diasend software to easily create your own food database and upload into your pump. This means you don’t need to worry about remembering all the carbohydrate amounts in the food you eat – it’s all there at the touch of a button. The best part is you have complete control of the items in your database and only includ Continue reading >>

6 New Diabetes Products To Look For In 2017

6 New Diabetes Products To Look For In 2017

If we learned anything about diabetes products in 2016, it’s that progress can happen faster than we anticipate. The diabetes community was stunned in September when the FDA announced that it had approved Medtronic Diabetes’ MiniMed 670G system, the world’s first pump/sensor system to be able to dose insulin on its own. (Advocacy works!) One of the most exciting things about the approval of Medtronic’s 670G is not only access to the groundbreaking device itself, but the path it paves for similar products – by many companies – to win approval as well. (We’re keeping an eye on Bigfoot Biomedical, Inc, the company that back in July of this year enrolled its first patients in a clinical trial for the Bigfoot smartloop automated insulin delivery system.) Now, as this year comes to a close, we’re listening to the buzz that continues to build around the new diabetes technology coming our way in 2017. The new year will bring a slate of highly anticipated products, including milestone devices like the OneTouch Via (a bolus-only delivery patch) and the above-mentioned Medtronic MiniMed 670G system (widely regarded as a rudimentary artificial pancreas). We’ve rounded up descriptions of some of the most exciting diabetes products expected to hit the market in 2017, followed by an approximate timeframe of when they’ll become available to the public. Sure, what we really want is a cure in 2017, but we’ll take improved quality of life, thanks to new devices and tech, with tremendous gratitude. Animas G5 Integrated Vibe Insulin Pump and CGM System What it is: This pump integrates Dexcom G5 technology with the Animas Vibe system. It’s especially exciting because it’s the only pump of its kind that is available to patients with type one diabetes as young as 2 ye Continue reading >>

Diabetes: Insulin Pumps After Injections And Cgm In T1dm

Diabetes: Insulin Pumps After Injections And Cgm In T1dm

A recent randomized controlled trial has shown that patients with type 1 diabetes mellitus who are treated with multiple daily insulin injections and continuous glucose monitoring (CGM) enjoy a further improvement in glycaemic control when switched to insulin pump therapy with CGM. However, some increase in biochemical hypoglycaemia was evident with pump treatment. Continue reading >>

More in insulin